Search

Your search keyword '"Lahat, Adi"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Lahat, Adi" Remove constraint Author: "Lahat, Adi" Journal gastroenterology Remove constraint Journal: gastroenterology
37 results on '"Lahat, Adi"'

Search Results

1. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)

2. CURCUMIN-QINGDAI COMBINATION FOR PATIENTS WITH ACTIVE ULCERATIVE COLITIS: A RANDOMIZED DOUBLE-BLINDED PLACEBO-CONTROLLED CLINICAL TRIAL

7. Su1762 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: 2 YEARS RESULTS OF THE LIBERTY-CD STUDY

9. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

10. Fr511 IMMUNE FUNCTION IN NEWBORNS OF FEMALES WITH GESTATIONAL ANTI- TNFα MEDICATION THERAPY FOR INFLAMMATORY BOWEL DISEASE

11. Mo1720 UNTARGETED SERUM METABOLOME SHOWS CROHN DISEASE (CD) ASSOCIATED SIGNATURE, SIGNALS THAT CORRELATE WITH DISEASE ACTIVITY AND CRP, AND SIGNALS THAT MAY PRECEDE DISEASE FLARE

13. 1028 SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD).

16. 948 A NOVEL SUBCUTANEOUS INFLIXIMAB (CT-P13) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: WEEK54 AND SWITCHING RESULTS FROM A MULTICENTER, RANDOMISED CONTROLLED PIVOTAL TRIAL

17. Tu1877 EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC RESULT IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFILXIMAB SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

18. Tu1715 – A Novel Formulation of Ct-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

19. 1150 – Intra-Personal Gut Microbial Variations in Patients with Quiescent Crohn Disease Predict Subsequent Disease Flare

21. 814 - Phase Iii Randomized Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab in Patients with Active Crohn's Disease: 1-Year Maintenance and Switching Results

22. 347 - Impact of Drug Levels, Anti-Drug Antibodies and α4β7 Target Occupnacy on the Response to Vedolizumab Therapy in Patients with Inflmmatory Bowel Disease

23. Tu2018 - Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: Initial Results from a Phase I Open-Label Randomized Controlled Trial in Patients with Active Crohn's Disease

24. 599 - Comprhensive Video Capsule Endosocpy-Based Monitoring Predicts Short and Long-Term Risk of Disease Flares in Small Bowel Crohn's Disease: A Prospective Cohort Study

25. Su1178 - Serum MMP-9 - A Novel Biomarker for Prediction of Clinical Relapse in Patients with Quiescent small Bowel Crohn's Disease

28. Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results

29. Tu1954 Capsule Endoscopy Findings and Fecal Calprotectin Levels Predict Clinical Relapse in Patients With Quiescent Small Bowel Crohn's Disease

30. Accuracy of Capsule Colonoscopy in Detecting Colorectal Polyps in a Screening Population

32. Sa1174 The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Classification of Disease in Patients With Known Crohn's Disease: A Prospective Israeli IBD Research Network (IIRN) Study

35. Mo1211 Oral Administration of Non-Absorbable Delayed Release 6-Mercaptopurine is Locally Active in the Gut, Exerts a Systemic Immune Effect and Alleviates Crohn's Disease With Low Rate of Side Effects: Results of Double Blind Phase II Clinical Trial

Catalog

Books, media, physical & digital resources